Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 2, 2006, Pages 179-191

  Nakajima, Yukiko ^a   Yoshitani, Takashi ^a   Fukushima Uesaka, Hiromi ^a   Saito, Yoshiro ^a   Kaniwa, Nahoko ^a   Kurose, Kouichi ^a   Ozawa, Shogo ^a   Aoyagi, Nobuo ^a   Kamatani, Naoyuki ^a   Yamamoto, Noboru ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a   Yoshida, Teruhiko ^a   Minami, Hironobu ^a   Saijo, Nagahiro ^a   Katori, Noriko ^a   Sawada, Jun ichi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' (4 HYDROXYPACLITAXEL); 6ALPHA HYDROXYPACLITAXEL; ANTIALLERGIC AGENT; CARBOPLATIN; CHLORPHENIRAMINE MALEATE; CREMOPHOR; CYTOCHROME P450 3A4; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG METABOLITE; NEDAPLATIN; PACLITAXEL; PREDNISOLONE; SERINE; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENZYME ACTIVITY; ETHNOLOGY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO;

ADULT; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EXCIPIENTS; FEMALE; HAPLOTYPES; HUMANS; JAPAN; MALE; NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 33746677973     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.04.012     Document Type: Article

References (36)

1. Martin V. Overview of paclitaxel (TAXOL). Semin Oncol Nurs 9 Suppl 2 (1993) 2-5
2. Horwitz S.B. Taxol (paclitaxel). mechanisms of action. Ann Oncol 5 Suppl 6 (1994) S3-S6
3. Ling Y.H., Yang Y., Tornos C., Singh B., and Perez-Soler R. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58 (1998) 3633-3640
4. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of Taxol by human hepatic microsomes and liver slices. participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54 (1994) 4026-4035
5. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., and Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275 (1995) 566-575
6. Cresteil T., Monsarrat B., Dubois J., Sonnier M., Alvinerie P., and Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8. structure-activity relationship. Drug Metab Dispos 30 (2002) 438-445
7. Monsarrat B., Chatelut E., Royer I., Alvinerie P., Dubois J., Dezeuse A., et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26 (1998) 229-233
8. Guengerich F.P. Cytochrome P-450 3A4. regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
9. Taniguchi R., Kumai T., Matsumoto N., Watanabe M., Kamio K., Suzuki S., et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 97 (2005) 83-90
10. Bork R.W., Muto T., Beaune P.H., Srivastava P.K., Lloyd R.S., and Guengerich F.P. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem 15;264 (1989) 910-919
11. Damkier P., and Brosen K. Quinidine as a probe for CYP3A4 activity. intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 68 (2000) 199-209
12. Ozdemir V., Kalowa W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., et al. Evaluation of the genetic component of variability in CYP3A4 activity. a repeated drug administration method. Pharmacogenetics 10 (2000) 373-388
13. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294
14. CYP3A4 allele nomenclature. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available from: URL:www.imm.ki.se/CYPalleles/cyp3a4.htm. Accessed Dec 21, 2005
15. Fukushima-Uesaka H., Saito Y., Watanabe H., Shiseki K., Saeki M., Nakamura T., et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23 (2004) 100
16. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W., et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299 (2001) 825-831
17. Murayama N., Nakamura T., Saeki M., Soyama A., Saito Y., Sai K., et al. CYP3A4 gene polymorphisms influence testosterone-6β-hydroxylation. Drug Metab Pharmacokinet 17 (2002) 150-156
18. Hsieh K.P., Lin Y.Y., Cheng C.L., Lai M.L., Lin M.S., Siest J.P., et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29 (2001) 268-273
19. Judson R., Stephens J.C., and Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 1 (2000) 15-26
20. Sparreboom A., de Bruijn P., Nooter K., Loos W.J., Stoter G., and Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 705 (1998) 159-164
21. Sparreboom A., Loos W.J., Verweij J., de Vos A.I., van der Burg M.E., Stoter G., et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255 (1998) 171-175
22. Saeki M., Saito Y., Jinno H., Tohkin M., Kurose K., Kaniwa N., et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin Chem 49 (2003) 1182-1185
23. Kitamura Y., Moriguchi M., Kaneko H., Morisaki H., Morisaki T., Toyama K., et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 66 (2002) 183-193
24. Soyama A., Saito Y., Hanioka N., Murayama N., Nakajima O., Katori N., et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 24 (2001) 1427-1430
25. Hichiya H., Tanaka-Kagawa T., Soyama A., Jinno H., Koyano S., Katori N., et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 33 (2005) 630-636
26. Sparreboom A., van Zuylen L., Brouwer E., Loos W.J., de Bruijn P., Gelderblom H., et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. clinical pharmacokinetic implications. Cancer Res 59 (1999) 1454-1457
27. Sparreboom A., van Tellingen O., Nooijen W.J., and Beijnen J.H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56 (1996) 2112-2115
28. Nakajima M., Fujiki Y., Kyo S., Kanaya T., Nakamura M., Maida Y., et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45 (2005) 674-682
29. Nakajima M., Fujiki Y., Noda K., Ohtsuka H., Ohkuni H., Kyo S., et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31 (2003) 687-690
30. Henningsson A., Karlsson M.O., Vigano L., Gianni L., Verweij J., and Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19 (2001) 4065-4073
31. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50 (1995) 222-239
32. Parkinson A., Mudra D.R., Johnson C., Dwyer A., and Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199 (2004) 193-209
33. Lamba J.K., Lin Y.S., Thummel K., Daly A., Watkins P.B., Strom S., et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12 (2002) 121-132
34. Sai K., Kaniwa N., Itoda M., Saito Y., Hasegawa R., Komamura K., Ueno K., et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13 (2003) 741-757
35. Henningsson A., Marsh S., Loos W.J., Karlsson M.O., Garsa A., Mross K., et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11 (2005) 8097-8104
36. Evans W.E., and Relling M.V. Pharmacogenomics. translating functional genomics into rational therapeutics. Science 286 (1999) 487-491